Bioms Medical Corporation (TSE:MS) to Release Q1 2008 Earnings May 12

Bioms Medical Corporation (TSE:MS) will release the first quarter earnings for 2008 on Monday, May 12.  The financial results will be made available at boimsmedical.com/quarterly_reports.asp.

BioMS Medical Corp. (BioMS) is a biotechnology company engaged in the development and commercialization of therapeutic technologies for the treatment of multiple sclerosis (MS).

During the year ended December 31, 2007, BioMS conducted a number of clinical trials with MBP8298: two pivotal Phase III clinical trials (MAESTRO-01 and MAESTRO-03), one open label trial (MAESTRO-02) in secondary progressive MS, and one Phase II trial in relapsing remitting MS (MINDSET-01).

During 2007, BioMS is conducted the MAESTRO-01 trial, a pivotal Phase II/III, multi-centre, double blind, placebo-controlled trial designed to evaluate the safety and efficacy of MBP8298 in patients with secondary progressive MS.

In January 2007, approval was received from the United States Food and Drug Administration for the initiation of the MAESTRO-03 trial, a pivotal Phase III clinical trial in the United States to investigate the use of MBP8298 as a treatment for patients with secondary progressive MS.

Find more Earnings events on Finditt Events.